linjc16/ctgov huggingface dataset:
Proton Therapy for Chordomas and/or Chondrosarcomas

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.

Detailed Description
-----------------
Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.

Official Title
-----------------
A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine

Conditions
-----------------
Chordomas, Chondrosarcomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven chordoma or chondrosarcoma. Sites: base of skull and/or spine. Age 18 years or older. Exclusion Criteria: Previous radiation to the head and neck or brain. Evidence of metastatic disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Proton Radiation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect and analyze outcome data on tumor control. |  | When each patient has been followed for a minimum of 12 month and then again after 24 months to a maximum of 10 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect and analyze data on normal tissue morbidity. | Specifically analyzing pituitary, visual and hearing function. | When each patient has been followed for a minimum of 12 months and then again after 24 months to a maximum of 10 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chordomas, Chondrosarcomas, Cancer, Outcomes, Proton radiation
Prognostic Value of PD-L1 in NSCLC

Study Overview
=================
Brief Summary
-----------------
This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC). Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or >50% of tumor cells express the ligand. The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.

Official Title
-----------------
The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Other: immunohistochemistry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Early stage treatment-naive NSCLC Exclusion Criteria: Received any pre-surgical treatment no OS data available

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression | The study will investigate PD-L1 protein expression by immunohistochemistry in tumor samples from early stage NSCLC | 15 days | 
| Prognostic value | The correlation between PD-L1 protein expression by immunohistochemistry and overall survival will be studied | 15 days |
Vestibular Socket Therapy (VST) Versus Partial Extraction Therapy

Study Overview
=================
Brief Summary
-----------------
The current randomized clinical trial aimed to compare the VST versus Partial Extraction Therapy (PET) for immediate implant placement in the esthetic zone in class I fresh extraction sites. The primary outcome was the assessment of vertical dimensional changes in peri-implant soft tissue margin. The secondary outcome was the assessment of radiographic changes in the thickness of the facial peri-implant tissues.

Official Title
-----------------
Vestibular Socket Therapy (VST) Versus Partial Extraction Therapy (PET) for Treating Fresh Extraction Sites With Thin Labial Plate of Bone With Immediate Implant Placement in the Esthetic Zone: A Randomized Clinical Trial

Conditions
-----------------
Dental Implants

Intervention / Treatment
-----------------
* Procedure: Class I extractions sites received immediate implants using the Vestibular Socket Therapy
* Procedure: class I extractions sites received immediate implants using the Partial Extraction Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: single hopeless maxillary tooth in the esthetic zone non-smokers systemically healthy Class I extraction sites Exclusion Criteria: smoking Class II and III extraction sites hopeless teeth with acute infection or vertical/horizontal root fracture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VST technique<br> | Procedure: Class I extractions sites received immediate implants using the Vestibular Socket Therapy<br>* A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision<br>|
| Active Comparator: PET technique<br> | Procedure: class I extractions sites received immediate implants using the Partial Extraction Therapy<br>* the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in the peri-implant facial tissue thickness | through CBCT images (Carestream 8000D- Carestream Dental) that were taken at baseline and 6 months postoperatively | at baseline and 6 months |
Efficacy of Resveratrol in Depression

Study Overview
=================
Brief Summary
-----------------
Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Official Title
-----------------
Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Resveratrol Pill
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (selectively): MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5); current depression. Exclusion Criteria (selectively): serious or unstable disease; antidepressants intake.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Resveratrol Pill<br> | Drug: Resveratrol Pill<br>* Resveratrol 500 mg<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebos<br>* Placebo Pills<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Total HDRS-17 Score From Baseline to Week 4 | Hamilton Depression Rating Scale 17 items, total score range 0-53 (53 - worse) | 4 weeks | 
| Change in SIRT1 Activity From Baseline to Week 4 | SIRT1 is enzyme sirtuin-1 which activity is measured in the blood | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Total BDI-II Score From Baseline to Week 4 | Beck Depression Inventory 21 items, total score range 0-63 (63 - worse) | 4 weeks |
TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry

Study Overview
=================
Brief Summary
-----------------
Quality Control Registry for IORT used as an anticipiated boost with 20 Gy at the applicator surface followed by EBRT

Detailed Description
-----------------
Quality Control Registry of a standard treatment with intraoperative radiotherapy during breast conserving surgery with 20 Gy at the applicator surface as an advanced boost followed by a shortened external beam radiotherapy. This is a prospective phase IV study to evaluate real life data of IORT Boost. Study runs in Germany with 13 active centers recruiting. Due to the nature of the study (registry) there is no need for randomization. Inclusion of n = >1000 patients is planned.

Official Title
-----------------
TARGeted Intraoperative radioTherapy With the INTRABEAM-System as an Advanced Boost in Patients With Breast Cancer - A Quality Control Registry in Germany (TARGIT BQR)

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Radiation: IORT with 50 kV x-rays, 20 Gy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tumor diameter < 3,5 cm Informed consent Exclusion Criteria: No informed consent Tumor size > 3,5 cm No indication for a boost

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IORT with 50 kV x-rays, 20 Gy<br>Boost with 20 Gy during BCS, EBRT with 46-50 Gy | Radiation: IORT with 50 kV x-rays, 20 Gy<br>* Intraoperative radiotherapy with the INTRABEAM System with 20 Gy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local recurrence rate |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity, Overall survival | LENT SOMA Scale for toxicity regular follow up | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IORT, Boost, Breast cancer, Local recurrence, Toxicity, LENT SOMA, TARGIT, Quality Control Registry
Lifestyle Related Disease Management With Wearable Device and Mobile Application

Study Overview
=================
Brief Summary
-----------------
In order to study the effectiveness of personalized healthcare intervention for lifestyle-related diseases, investigators designed this study using mobile application and clinical feedback coaching.

Official Title
-----------------
A Study of the Management of the Patient's Disease Based on the Life Log Data of Patient With Lifestyle-related Diseases Through a Wearable Device and Mobile App

Conditions
-----------------
Life Style Induced Illness, Obesity

Intervention / Treatment
-----------------
* Behavioral: Personalized healthcare service


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study participants must agree to support by him/herself at enroll time Patient without severe cardiopulmonary disease, cancer, or other acute diseases Patient must be over BMI > 23 kg/m2 Exclusion Criteria: Patient who did not agree with this study Patient with severe cardiopulmonary disease, cancer, or other acute diseases Patient who are pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Personalized lifestyle intervention group<br>Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician | Behavioral: Personalized healthcare service<br>* Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring<br>|
| No Intervention: Conventional group<br>Patients with conventional care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight change | Measuring weight change | Baseline and after 2 weeks, 4 weeks of lifestyle modification | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body composition change | Measuring body composition | Baseline and after 2 weeks, 4 weeks of lifestyle modification | 
| Laboratory test result change | Obstructive sleep apnea test | Baseline and after 2 weeks, 4 weeks of lifestyle modification |
Pregnancy Outcome in Woman With Threatened Abortion

Study Overview
=================
Brief Summary
-----------------
The study aims to quantify the relations between first & second trimester bleeding and maternal & neonatal morbidity. Additionally, the study will help in assessing the risk for abortions in women with threatened abortions and the risk factors for threatened abortion.

Detailed Description
-----------------
the study is following woman retrospectively through their pregnancy from the first trimester troughout delivery . we will measure the relation between first and/or second trimester bleeding ( threatend abortion ) and pregnancy outcome ( as written below ) - maternal and neonatal .

Official Title
-----------------
Pregnancy Outcome in Woman With Threatened Abortion

Conditions
-----------------
Threatened Abortion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who attended the Emergency department with vaginal bleeding and/or abdominal pain and were on their 20th week of pregnancy or less. Exclusion Criteria: Women with any background that can explain vaginal bleeding or any other circumstance that can explain it.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal and neonatal outcome in pregnancies with 1st and 2nd trimester bleeding | by using our data in the past 7 years we will examine retrospectively cases of patients from their first admission due to vaginal bleeding throgh their pregnancy and labor . the mesearment will include : Intra uterine growth retardation , Antepartum hemorrhage, premature rupture of membrane, Intra uterine fetal death , Preterm delivery, Apgar less than 7, Congenital malformation, Mode of delivery - vaginal delivery vs. cesarean section | 9 months |
Macro-scale Estimators of Covid-19's Worldwide Cases and Deaths

Study Overview
=================
Brief Summary
-----------------
In this study, investigators try to estimate Covid-19 Cases and Deaths using countrywide annual macro-scale indicators (i.e., estimators) such as non-communicable disease data from WHO (who. int), social and economical indicators from UN (un.org) and Worldbank (worldbank.org), and Covid-19 Cases and Deaths from Worldometer (https://www.worldometers.info).

Detailed Description
-----------------
There are some known risk factors for the emergence and mortality of Covid-19 cases. There are also some regulations and recommendations by healthcare executives and government officers such as wearing masks, social distance, staying at home, lockdowns, and so forth. On the other hand, there could be other social, economic, and health-related factors in the society level that discriminate between countries significantly in terms of having considerable differences regarding both the frequency and mortality of Covid-19. The aim of the present study is to find out these social, economic, and health-related factors that could explain some significant portion of Covid-19 cases and deaths worldwide. This study involves 171 countries of which required datasets are commonly available in the UN, Worldometer, and WHO. The investigators will obtain macro-scale indicators like non-communicable disease data from WHO (who. int), social and economical indicators from UN (un.org) and Worldbank (worldbank.org), and Covid-19 data from Worldometer (https://www.worldometers.info). The investigators will conduct statistical data analysis and create predictive models in order to determine indicators. The investigators will also consider that possible different models for explaining Covid-19 Cases and mortality in both common and different estimators could explain the variations in countrywide deaths and cases.

Official Title
-----------------
Determination of the Macro Scale Risk Factors in COVID19 Occurrence and Mortality

Conditions
-----------------
COVID19

Intervention / Treatment
-----------------
* Other: frequency


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All recorded cases by the authority Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: frequency|Macro-scale risk factors for the frequency of and mortality of infection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurence | The frequency of infection according to publicly available data | december 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | The mortality of infection according to publicly available data | december 2020 |
Evaluation of Immune Signaling Networks in Healthy Human Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to better understand whether and to what extent the activity of immune cells in blood varies over time under normal conditions as assessed in healthy subjects. Results of this study will provide the foundation for helping us evaluate changes in immune cell activities in response to surgery and drugs used in anesthesia. The overall purpose of our research is to understand immune health in the context of anesthesia and surgery.

Official Title
-----------------
Evaluation of Immune Signaling Networks in Healthy Human Volunteers

Conditions
-----------------
Normal Immune Cell Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-50 Good general health Exclusion Criteria: Recent cold or flu Chronic use of medications affecting the immune system Chronic illness Smoking habit History of drug abuse Current recreational drug use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical and functional changes of circulating immune cells over time in healthy individuals | This is an exploratory study. Numerical and functional (phosphorylation of signaling molecules and transcription factors) behavior of all circulating immune cells will be captured. Blood specimens collected at referenced time points will be analyzed with mass cytometry. | Day 1, Day 2, Day 7, Day 28 |